Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? (Q35674392)

9 August 2017

1 reference

title

Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? (English)

1 reference

9 August 2017

Michael P Busch

1 reference

9 August 2017

publication date

1 February 2004

1 reference

Transfusion Clinique et Biologique

9 August 2017

published in

1 reference

9 August 2017

1 reference

9 August 2017

1 reference

9 August 2017

page(s)

26-32

1 reference

HBV: amplified and back in the blood safety spotlight

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Comparative sensitivity of HBV NATs and HBsAg assays for detection of acute HBV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Analysis of HBV infection after blood transfusion in Japan through investigation of a comprehensive donor specimen repository

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

NAT for HBV and anti-HBc testing increase blood safety

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Type B hepatitis after transfusion with blood containing antibody to hepatitis B core antigen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Comparison of the sensitivity of NAT using pooled donor samples for HBV and that of a serologic HBsAg assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Serological pattern ?anti-HBc alone?: Report on a workshop

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Evidence that anti-HBc but not HBV DNA testing may prevent some HBV transmission by transfusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

New hepatitis B virus mutant form in a blood donor that is undetectable in several hepatitis B surface antigen screening assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Frequency of HBV DNA detection in US blood donors testing positive for the presence of anti-HBc: implications for transfusion transmission and donor screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

Mathematic modeling of the risk of HBV, HCV, and HIV transmission by window-phase donations not detected by NAT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRACLI.2003.12.003

10.1016/J.TRACLI.2003.12.003

7 January 2021

Identifiers

DOI

1 reference

9 August 2017

1 reference